Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

A Study of Urine Volatile Organic Compounds for Disease Detection (TOBY ATLAS)

9 novembre 2026 mis à jour par: Toby, Inc.

TOBY ATLAS: A Multi-Site, Non-Interventional Study of Urinary Volatile Organic Compounds

The goal of this observational study is to develop and evaluate urine tests for detecting disease in adults. It will initially focus on prostate, bladder, and kidney cancer. Researchers will compare urine samples and medical records from people with and without these diseases to see whether the tests can detect them accurately. Participants may provide a urine sample during a routine visit. Study results will not be returned to participants or used in their care.

Aperçu de l'étude

Statut

Pas encore de recrutement

Description détaillée

TOBY ATLAS is a multi-center master protocol that supports the development and validation of urine-based tests for screening, diagnosis, and monitoring of multiple diseases. The study uses prospectively collected, residual, banked, and purchased urine samples, where permitted.

Researchers will analyze urine for volatile organic compounds using gas chromatography-mass spectrometry and develop models using samples with known disease status. Each model will be locked before it is evaluated using a separate set of blinded samples.

Disease status and available standard-of-care test results will be obtained from medical records. Researchers may also review records over time to identify later diagnoses or outcomes. Sites and diseases may be added as the study progresses.

Type d'étude

Observationnel

Inscription (Estimé)

30000

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: TOBY ATLAS Study Team
  • Numéro de téléphone: 309-592-8898
  • E-mail: info@toby.health

Sauvegarde des contacts de l'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

Adults with target diseases and comparison participants, including healthy volunteers and individuals with other diseases, benign conditions, or negative diagnostic work-ups. Participants are identified through routine care and other permitted specimen sources.

La description

Inclusion Criteria:

  • Age 50 years or older, or another age range set in the applicable disease specification (for example, 45 or older for colorectal cancer).
  • Informed consent, or eligibility under an exemption or waiver for waste, residual, banked, or purchased specimens.
  • Medical records available for the reference standard.
  • Meets the case or control definition and other inclusion criteria in at least one disease specification, or belongs to the Healthy Control Set.

Exclusion Criteria:

  • Any exclusion stated in the applicable disease specification.
  • Symptomatic urinary tract infection at collection, unless enrolled as a confounder control.
  • Current pregnancy, imprisonment, or inability to consent for oneself (consented route).

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: CASE_CONTROL
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Target disease cases

Participants with a target disease established by the applicable reference standard, including participants assessed after treatment where specified.

Controls

Participants without the target disease for a given analysis, including healthy participants and participants with other diseases, benign conditions, or negative diagnostic work-ups.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Clinical performance of each locked assay
Délai: At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.

Sensitivity and specificity at pre-specified thresholds, and area under the receiver operating characteristic curve, of each locked assay against the applicable reference standard in its intended-use population, using blinded validation specimens not used to develop that assay. Estimates will include 95% confidence intervals.

At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
Paired comparison with available standard-of-care tests
Délai: At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.

Differences in sensitivity, specificity, and area under the receiver operating characteristic curve between each locked assay and each available standard-of-care test in the same participants, with 95% confidence intervals.

At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Assay performance by subgroup and signal origin
Délai: At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.

Sensitivity, specificity, and area under the receiver operating characteristic curve across thresholds and by disease characteristics, populations, and control types, including stage, grade, and age; accuracy of signal-origin classification.

At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
Protocol-conforming specimens with final reference-standard classification
Délai: From specimen collection through reference-standard classification, including medical-record review at approximately 12 months where available.

Number of protocol-conforming urine specimens with final reference-standard classification, summarized by disease and control type.

From specimen collection through reference-standard classification, including medical-record review at approximately 12 months where available.

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Candidate assays advanced to validation
Délai: From study start through study completion, estimated up to 5 years

Number of candidate assays developed using the Development Pool that are locked and carried forward to a Validation Plan.

From study start through study completion, estimated up to 5 years
Exploratory prognostic and simulated clinical and economic outcomes
Délai: Up to 5 years after specimen collection, where follow-up is permitted and available

Where optional medical-record follow-up is available, compare progression, recurrence, treatment response, stage at diagnosis, procedures, health care use, and costs with blinded assay predictions. These are exploratory prognostic and simulated health-economic analyses; test results are not used in care.

Up to 5 years after specimen collection, where follow-up is permitted and available

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 janvier 2027

Achèvement primaire (Estimé)

1 janvier 2032

Achèvement de l'étude (Estimé)

1 janvier 2032

Dates d'inscription aux études

Première soumission

4 novembre 2026

Première soumission répondant aux critères de contrôle qualité

9 novembre 2026

Première publication (Réel)

12 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

9 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

There is currently no plan to make individual participant data available to other researchers.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner